Publication details
Trajektorie změn I v přístupu k terapii diabetu 2. typu v postproduktivním věku během uplynulých 12 let, perorální antidiabetika - vlastní zkušenost
| Title in English | Trajectories of changes I - in the approach to oral hypoglycemic therapy of type 2 diabetes in post-productive age during the past 12 years - our own experience |
|---|---|
| Authors | |
| Year of publication | 2020 |
| Type | Article in Periodical |
| Magazine / Source | Geriatrie a gerontologie |
| MU Faculty or unit | |
| Citation | |
| web | http://www.prolekare.cz/casopisy/geriatrie-gerontologie |
| Keywords | Diabetes; old age; treatment options with oral hypoglycemic drugs; changes in aproach to therapy in the past 12 years |
| Description | Trajectories of changes I - in the approach to oral hypoglycemic therapy of type 2 diabetes in post-productive age during the past 12 years - our own experience. Diabetes mellitus (DM) at any age significantly affects the health status and other perspectives (such as late complications) of an individual´s life. During 2019, 2332 patients with type 2 DM (DM2T) were treated in our diabetological outpatient clinic DIASTOP. Of these, 1562 were treated with oral antidiabetic drugs (OAD) and/or diet alone. In the sample, we analyzed: age, duration of diabetes, obesity, diabetic complications and type of therapy, in particular we focused on the changing trends in DM2T treatment over the past 12 years (i. e. 2008-2019). Analysis of DM2T therapy over 12 years showed a significant decrease in the use of mere diabetic diet (37,5 % in 2008 to 13 % in 2019) and sulphonylurea (from 42,8 % in 2008 to 24 % in 2019), while the use of metformin in the treatment of DM2T increased significantly (from 19,5 % in 2008 to 65 % in 2019), both as monotherapy and in combination with other drugs (especially gliptins). We also observed a steady trend in the increase in the use of new oral hypoglycemic drugs (OADs) during those years, with the following being used in 2019: pioglitazone in 11,0 % DM2T; gliptins (DPP4 inhibitors in 43 %) andgliflozins (SGLT2 inhibitors - 4 %). Our communication points to a massive shift and change of approach in DM2T therapy in the last decade in common outpatient practice in the use of OAD. |
| Related projects: |